Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[BCG Today].

Daniel Lévy-Bruhl1

  • 1Institut de veille sanitaire, Département des maladies infectieuses, Saint-Maurice (94).

Presse Medicale (Paris, France : 1983)
|November 7, 2006
PubMed
Summary

France shifted its BCG vaccination policy, discontinuing routine revaccinations and post-vaccination tests. A selective approach for high-risk children is now favored, alongside enhanced tuberculosis control measures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decreases in influenza vaccination coverage among nursing home healthcare workers and in measures to promote influenza vaccination, France, 2007/08 to 2024/25.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

Modelling the impact of a quadrivalent ACWY meningococcal vaccination and vaccination targeting serogroup B in France.

Vaccine·2025
Same author

Keeping schools open during the emergence of the COVID-19 alpha variant: Impact on the circulation of SARS-CoV-2 among children during the 2020-2021 school year: Epidemiology of COVID-19 in children and adolescents during the 2020-2021 school year in France.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2024
Same author

Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2024
Same author

Contributions of the qualitative Qualicor study embedded in a cohort study on the circumstances of SARS-CoV 2 infection in France.

Infectious diseases now·2024
Same author

What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.

Vaccine·2023

Area of Science:

  • Public Health
  • Infectious Disease Epidemiology
  • Vaccination Policy

Background:

  • French BCG vaccination policy historically mandated pre-entry vaccination and revaccination for tuberculin-negative children.
  • Policy reassessment in 2004 led to the discontinuation of routine revaccinations and post-vaccination tuberculin tests.
  • The multipuncture BCG vaccine, used for over 90% of primary vaccinations, was withdrawn in 2006, complicating vaccination strategies.

Purpose of the Study:

  • To evaluate the epidemiological effects of selective BCG vaccination versus complete discontinuation.
  • To analyze the risks and benefits associated with different BCG vaccination strategies.
  • To inform public health policy regarding childhood tuberculosis prevention in France.

Main Methods:

  • Epidemiological assessment of vaccination strategies.
  • Risk-benefit analysis of selective versus universal BCG vaccination.
  • Review of public health recommendations and policy changes.

Main Results:

  • The High Council of Public Hygiene approved the principle of selective BCG vaccination for children.
  • Reinforcement of other tuberculosis control measures was advised as a prerequisite for selective vaccination.
  • The discontinuation of routine revaccinations and post-vaccination tests was implemented in 2004.

Conclusions:

  • France has transitioned from universal BCG vaccination to a selective strategy for high-risk children.
  • Enhanced non-vaccine-related tuberculosis control measures are crucial for protecting children.
  • The policy shift reflects an updated risk-benefit assessment in light of epidemiological data and vaccine availability.

Related Experiment Videos